anayamalik, Author at European Medical Journal - Page 63 of 128

Emerging Biologics in Treating Pemphigus and Bullous Pemphigoid

Emerging immunotherapies are transforming the treatment landscape for pemphigus and bullous pemphigoid, two distinct autoimmune blistering skin diseases marked by pathogenic autoantibodies and significant patient burden.

AI Image Analysis Predicts BRAF Mutation Status

A novel artificial intelligence pipeline can predict BRAF mutation status directly from histopathology slides, marking a potential step forward in digital dermatopathology and melanoma care.

Fungal Threats Rising as Climate Changes

Climate change is accelerating the emergence and spread of dangerous fungal infections, expanding their range and resistance in ways that could reshape global public health.

Key Appointments Being Missed After Adolescent and Young Adult Cancer

A new study reveals significant gaps in follow-up care among survivors of adolescent and young adult (AYA)–onset cancers, with nearly one in five missing all oncology specialty visits during the surveillance period.

New Insights into VMAT2 Use for Child Movement Disorders

VMAT2 inhibitors may offer effective symptom relief for pediatric hyperkinetic movement disorders, according to a new retrospective study reviewing over a decade of clinical use.

Bronchoscopy Beats CT for Lung Nodule Precision

Electromagnetic navigation bronchoscopy (ENB)-guided dye marking offers a safer, faster alternative to CT-guided lung puncture for preoperative localization of multiple ipsilateral pulmonary nodules, according to a new retrospective cohort study.

How Can the Gut Heal Orthopaedic Pain?

The gut microbiome may hold untapped potential in managing pain related to orthopaedic conditions, according to a new integrative review that highlights its emerging role in modulating inflammation and neurological pathways.

IL-23 Inhibitor Resolves Severe Psoriasis Triggered by Adalimumab

In a compelling case that underscores the complexity of biologic therapies, a patient with hidradenitis suppurativa (HS) developed adalimumab-induced pustular psoriasis, which was successfully treated with guselkumab.

New Combo Therapy Delays HER2+ Breast Cancer: ASCO 2025

Trastuzumab deruxtecan combined with pertuzumab significantly delayed disease progression compared to standard care in patients with HER2-positive advanced breast cancer, according to initial findings from the DESTINY-Breast09 Phase III trial.

Breast Cancer Survivors Show Unexpected Lower Alzheimer’s Risk

Breast cancer survivors may face a lower risk of Alzheimer’s disease than their cancer-free peers, according to a large retrospective cohort study examining long-term cognitive outcomes following treatment.